Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis
Philip Joseph(Population Health Research Institute), Salim Yusuf(Population Health Research Institute), Reza Malekzadeh(Shiraz University of Medical Sciences), Dorairaj Prabhakaran, Anthony Rodgers(New South Wales Department of Health), Eva Lonn(McMaster University), Lisheng Liu(Chinese Academy of Medical Sciences & Peking Union Medical College), Jun Zhu(Xinjiang Medical University), Patricio López‐Jaramillo(Universidad De Santander), Karen Sliwa(University of Cape Town), Shrikant I. Bangdiwala(Health Sciences Centre), Habib Gamra(Hospital Fatuma Bourguiba Monastir), Gholamreza Roshandel(Golestan University), Koon Teo(Population Health Research Institute), Mark D. Huffman(The George Institute for Global Health), Denis Xavier(McMaster University), Valentı́n Fuster(Spanish National Centre for Cardiovascular Research), Jackie Bosch(Universidade Federal do Rio Grande do Sul), Álvaro Avezum(Hospital Alemão Oswaldo Cruz), Prem Pais(St.John's Medical College Hospital), Gilles R. Dagenais(Institut universitaire de cardiologie et de pneumologie de Québec), Peggy Gao, José M. Castellano(Hospital de Sant Pau), Antonio Dans(University of the Philippines Manila), Rafael Díaz(Estudios Clínicos Latinoamérica)
Cited by 148
Related Papers
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2009|11.2k
Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
|New England Journal of Medicine|2008|7.4k
Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis
|The Lancet|2015|3.7k
Selected major risk factors and global and regional burden of disease
|The Lancet|2002|3.6k
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
|New England Journal of Medicine|2018|3.5k